Inhibition of Histone Deacetylase 6 (HDAC6) combined with the immune checkpoint blockade (anti-PD-L1) can treat ARID1A-mutated OCCC by enhancing cytotoxic T cell activity and modulating the tumor immune microenvironment (Fukumoto et al., 2019). This evidence concerns the gene ARID1A and neoplasm.